Senti Bio rises on FDA clearance to start trials on blood cancer therapy

Senti Biosciences Holdings

22/12/2023 14:51

** Shares of drug developer Senti Bio  SNTI.O  rise as much
as 34.1% to a more than one-month high of $0.59 in early trading
    ** Co says the U.S. FDA has given it clearance to start
clinical trials on its gene therapy for types of blood cancers  
  
    ** SNTI plans to begin an early-stage trial next year and
expects to disclose initial efficacy data by the end of 2024    
     
    ** Despite session's gain, stock down 62.2% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))